Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib maintenance after autologous stem cell transplantation for mantle cell lymphoma
ChiCTR2100054731Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by Henan Cancer Hospital. Primary endpoints: Bone marrow aspiration and bone marrow biopsy, CT and 3 more. Started Jan 2022; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR2100054731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054731.